During the last three months, 4 analysts shared their evaluations of Baxter Intl (NYSE:BAX), revealing diverse outlooks from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Baxter Intl and provided 12-month price targets. The average target is $38.0, accompanied by a high estimate of $42.00 and a low estimate of $35.00. Surpassing the previous average price target of $37.50, the current average has increased by 1.33%.

Breaking Down Analyst Ratings: A Detailed Examination

A comprehensive examination of how financial experts perceive Baxter Intl is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Baxter Intl's market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Baxter Intl analyst ratings.

Unveiling the Story Behind Baxter Intl

Understanding the Numbers: Baxter Intl's Finances

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: Baxter Intl displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 0.99%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Baxter Intl's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -18.6%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Baxter Intl's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -6.9%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Baxter Intl's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.95%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Baxter Intl's debt-to-equity ratio stands notably higher than the industry average, reaching 1.93. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

The Significance of Analyst Ratings Explained

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.